Health Care [ 6/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies.
The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 25, 25 | -1.09 Decreased by -163.01% | -1.22 Increased by +10.35% |
| Nov 5, 24 | -1.17 Increased by +4.10% | -1.16 Decreased by -0.86% |
| Aug 6, 24 | -1.11 Decreased by -2.78% | -1.13 Increased by +1.77% |
| May 7, 24 | -1.21 Increased by +9.02% | -1.42 Increased by +14.79% |
| Feb 27, 24 | 1.73 Increased by +420.37% | -1.01 Increased by +271.29% |
| Nov 8, 23 | -1.22 Increased by +21.79% | -1.36 Increased by +10.29% |
| Aug 8, 23 | -1.08 Decreased by -5.88% | -1.42 Increased by +23.94% |
| May 10, 23 | -1.33 Decreased by -31.68% | -1.34 Increased by +0.75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 30.07 M Decreased by -90.49% | -90.35 M Decreased by -163.27% | Decreased by -300.51% Decreased by -765.41% |
| Sep 30, 24 | 14.27 M Decreased by -17.01% | -96.67 M Decreased by -0.60% | Decreased by -677.47% Decreased by -21.22% |
| Jun 30, 24 | 11.77 M Decreased by -41.48% | -91.05 M Decreased by -10.00% | Decreased by -773.45% Decreased by -87.96% |
| Mar 31, 24 | 7.41 M Decreased by -69.39% | -98.67 M Decreased by -17.42% | Decreased by -1.33 K% Decreased by -283.60% |
| Dec 31, 23 | 316.19 M Increased by +1.48 K% | 142.80 M Increased by +472.36% | Increased by +45.16% Increased by +123.60% |
| Sep 30, 23 | 17.19 M Increased by +8.82% | -96.09 M Increased by +12.31% | Decreased by -558.88% Increased by +19.42% |
| Jun 30, 23 | 20.12 M Increased by +20.80% | -82.78 M Decreased by -70.67% | Decreased by -411.49% Decreased by -41.28% |
| Mar 31, 23 | 24.21 M Increased by +187.10% | -84.03 M Decreased by -52.25% | Decreased by -347.12% Increased by +46.97% |